AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
S
Sandeep Batra, MD
Primary Investigator
Overview
The purpose of this study is to compare the effects good and/or bad of carboplatin with cisplatin on people with standard risk germ cell tumors to find out which is better.
Description
This phase III trial studies how well active surveillance, bleomycin, carboplatin, etoposide, or cisplatin work in treating pediatric and adult patients with germ cell tumors. Active surveillance may help doctors to monitor subjects with low risk germ cell tumors after their tumor is removed. Drugs used in chemotherapy, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
germ cell tumor
-
Age: - 49 Years
-
Gender: All
Inclusion Criteria
In order to be eligible to take part in this trial, patients must meet the following criteria:
In order to be eligible to take part in this trial, patients must meet the following criteria:
- Up to 49 Years (Child, Adult)
- Low risk stratum (stage I ovarian immature teratoma and stage I malignant GCT [all sites])
- Standard risk 1: Patient must be < 11 years of age at enrollment
- Standard risk 2: Patients must be >= 11 and < 25 years of age at enrollment
- Low risk stage I immature teratoma (IT); site: ovarian
- Low risk stage I MCGT; site: ovarian, testicular, or extragonadal
- Standard risk 1 (SR1); site: ovarian, testicular, or extragonadal
- Standard risk 2 (SR2); site: Ovarian, testicular, extragonadonal
For a full list of participation criteria, please visit clinicaltrials.gov.
Additional Information:Participants will not be paid for their participation.
Updated on
25 Apr 2024.
Study ID: 1904451893 (1705463860) (PHO-COG-FALLON-AGCT1531)
Connect with a study center near you
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact